USMLE-Rx

What is USMLE-Rx and who sells it?

The home page describes an all-in-one study companion: a Qbank, flashcards, videos and more in one connected system. It lists 5,000 plus board-style questions, 900 plus Bricks, 14,000 plus flashcards and more than 90 hours of video. It also says more than 100,000 students use it and cites a 4.7 App Store rating. All of those are vendor claims.

The seller is MedIQ Learning, LLC, a Kentucky limited liability company per its terms. The mobile apps carry the ScholarRx brand, and none of the pages read explain how ScholarRx and MedIQ relate, so both names are reported. No founding year, funding history or ownership change is published. The vendor's copyright line runs from 2006 to 2016, which suggests the product dates from about 2006, though that is an inference from a footer.

The vendor's terms state that McGraw-Hill and the NBME are not affiliated with the product.

What is in the product line?

Qmax is the question bank for Step 1 and Step 2 CK, with self-assessments, listed at 5,000 plus questions on the pricing page. Rx Bricks are 900 plus interactive modules with 4,000 plus review questions, per the vendor's pricing page. Express Videos for Step 1 run 90 plus hours with a workbook and between 1,200 and 1,300 topics, depending on the page. Flash Facts for Step 1 are 14,000 plus spaced-repetition cards with a feature called Study Stream. Rx360+ bundles these, with SmartNotes and analytics, and the home page offers a free study planner.

The counts do not agree across pages. The pages give 4,600, 5,000 and 5,300 questions, and 80 and 90 hours of video. A buyer who cares about a particular number should treat each as an approximate vendor claim and ask before relying on it.

What does it do well?

Breadth at a moderate price is the plain case for it. A student can buy only the part they need, a bank or videos or cards, in terms from 1 to 36 months, per the pricing page. That is more flexible than a single fixed-length bank.

Per the pricing page, plans are billed once for the duration shown, do not auto-renew, and the buyer is not charged again. A subscription that simply ends is a relief to anyone who has been caught by renewals elsewhere.

Per the page, Rx360+ can be tried free for 5 days with no credit card, so a buyer can see the question style, the videos and the cards before paying.

Blueprint's review calls it "a Step 1 study ally". That is praise from a competitor, which makes it a mild endorsement, and it is the only outside assessment.

Where does it fall short?

The first gap is evidence. No independent data on how USMLE-Rx users score is published. One 2025 observational study in the Journal of Medical Ethics uses USMLE-based ethics scenarios to test ChatGPT. It does not evaluate the product.

The second is price presentation. The pricing page shows two figures for each plan and does not label which is the original and which the sale price. The first figure reads as list and the second as the sale price, which matches a 35 percent promotion on 12-month plans and longer ($299 x 0.65 = $194.35).

The third is refunds. The pricing page has no refund policy, and the terms we read mention termination without refund for breaches and nothing else on refunds. A buyer should ask before paying, since a no-auto-renew plan can still be a large one-time charge.

What does it cost?

The headline figure is $299 list for a 12-month Qmax plan, $194.35 during the 35 percent sale, charged once, as of October 2026 per the vendor's pricing page. Rx360+ is $399 list ($259.35 on sale) and the Express Videos, Rx Bricks and Flash Facts plans are priced separately. Sale terms, shorter durations, the trial, the group and scholarship offers and the extended Rx360+ price points are in the pricing section.

How does it compare with UWorld and the video courses?

Against UWorld, the lower price is the main difference. A 12-month Qmax at list is $299 per the vendor, against $579 for UWorld's 360-day Step 1 or Step 2 CK QBank per UWorld's product pages. The UWorld bank lists 3,600 plus Step 1 questions per its page, and USMLE-Rx lists 5,000 plus, so the count favors Qmax. We have no source comparing question quality, difficulty or how well either predicts exam performance, so price and count are all we can compare. A student who wants UWorld's name and budgets for it should do so. A student who wants a cheaper bank can use the 5-day Rx360+ trial before deciding.

Against Boards and Beyond and Pathoma, the comparison is among video products. Express Videos are $149 for 12 months per the pricing page. Pathoma is $99.95 for 12 months per its sign-up page, with a single subject and a single teacher. Boards and Beyond runs from $24 for a week to $399 for two years per its pricing page, with a single course covering more than 490 Step 1 videos per McGraw Hill's guide. Express Videos cost more than Pathoma and cover more subjects.

Against AMBOSS, the difference is the library. AMBOSS bundles a reference library and bills its question bank separately, per its pricing page. USMLE-Rx has no library of that kind in the sources we read.

Is there independent feedback?

Hardly any. No community reviews and no 2025 or 2026 complaints are published, and the one outside assessment is Blueprint's, from a competitor. The pricing page refers to a group discount offer and a student scholarship, and the details of both were not retrieved. Anyone who qualifies should look at both before paying list price.

Who should buy it, and who should not?

A student who studies from First Aid and wants a bank, videos and cards from one vendor should compare the 12-month Rx360+ plan with the cost of assembling the same pieces elsewhere, and a student who wants only questions should look at Qmax alone. A PGY-1 paying out of pocket for a Step 3 review should note that the product pages read describe Step 1 and Step 2 CK, and no Step 3 offering is listed. A student who wants a reference article beside each question should price AMBOSS instead. Whoever buys should start with the 5-day trial, since the pricing page publishes no refund policy.

The verdict

USMLE-Rx is a fair-value bundle with no outcome data behind it. Buy the part you need on a term you will use and take the trial first. A 12-month Rx360+ plan at $259.35 on sale is a one-time charge with no stated refund route, so get the refund terms in writing before paying it.